Register
Login:
Share:
Email Facebook Twitter




Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 119.50Bid: 116.00Ask: 123.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 7.00Spread as %: 6.03%Open: 116.00High: 119.50Low: 116.00Yesterday’s Close: 119.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
119.50

Share Price SpacerBid
116.00

Share Price SpacerAsk
123.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
18,948

Share Price SpacerOpen
116.00

Share Price SpacerHigh
119.50

Share Price SpacerLow
116.00

Share Price SpacerClose
119.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.29m £73.24m 2,000

52 Week High 185.00 52 Week High Date 2-MAR-2015
52 Week Low 112.50 52 Week Low Date 9-NOV-2015

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
9 1,220 17,728 -4.121 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

05-Feb-16
16:17:54
116.25
295
Sell* 
116.00
123.00
342.94
Trade Type:
Ordinary

05-Feb-16
14:15:30
119.00
830
Buy* 
116.00
120.00
987.70
Trade Type:
Ordinary

05-Feb-16
11:47:35
118.00
8,632
Buy* 
115.00
120.00
10.19k
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>


Date/TimeAuthorSubjectShare PriceOpinion
Fri 21:06ChrisatrdgDMD article - comments119.50Strong Buy
Comments per waterloo01 from the other Board:

Chris, fair assessment and from where I sit I'd say Summit was rather well placed (as long as it works).

Summit - phase 2 shortly. 1st results end 2016
Biomarin - major FDA setback (unlikely to get approval IMO)
Sarepta - major FDA setback (likely to require larger study IMO. Under way I think)
Santhera - looks OK but is not a cure but treatment, so potential for combi use
PTC Therapeutics - doubt would get FDA approval without more trials. Of limited benefit.
Pfizer- not a cure but treatment. phase 2 results 2018
FibroGen - not a cure but treatment. phase 2 results 2018 (non walking boys so different target)
Akashi - major setback. Trial on hold. Safety issues
Catabasis - not a cure but treatment, so potential for combi. Phase 2 starting later 2016
Capricor - not a cure and on the wilder side of treatments. Phase 1
Fri 17:18ChrisatrdgDMD article119.50Strong Buy
'Recent Setbacks Have Duchenne Investors On Edge' - article is per link below at least Summit is now mentioned along with the Biomarin's of this world:

http://seekingalpha.com/article/3866666-recent-setbacks-duchenne-investors-edge
Fri 14:32Free-MoneyRE: Priced to buy118.00No Opinion
Yep, we seem to be a rising stock again. I guess people realise it's now very oversold and there is huge upside for traders.
Obviously investors know there is a massive upside from here.... just need to wait for the news flow and the science/business chaps to work their magic. GLA
Fri 12:13FootieladBazPriced to buy118.00Strong Buy
my latest purchase has just shown up...def time to buy in my opinion.
GLA
Thu 21:20LeKingEricNasdaq116.00No Opinion
What is going on in America?? Do they know something we don't??
Thu 11:48ChrisatrdgGood posts this morning116.00Strong Buy
Hi All again,

Good posts this morning.

I agree with Free-Money on his thoughts on C-Diff and DMD as it is exactly how I think it will pan out.

I remember Glynn saying at one of the meetings that if C-Diff at phase 2 was positive it could take up to 6 months to come up with a deal but before that we await an update on C-Diff on the nature of the strains encountered.

At the conference call on C-Diff Glynn said that they had high level results but not the detail as to which strains of C-Diff had been 'defeated' but that the trials in the USA and Canada were hopefully sufficiently wide spread to have caught some of them hence the design of the trials. I believe that Summit thinks that statistically they should have caught some of the more virulent strains.

Fingers crossed for positive news this quarter on DMD and C-Diff.

With regards the current SP as I have said before they are currently as 'Cheap as chips' - in my opinion worth a punt.

Finally I am looking forward to the AGM at which there will be many questions not sure about the champagne.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.






Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.